Pinned Tweet
Grateful to have met @MattHeineman at @dartmouth @HopkinsCenter at the screening of AMERICAN SYMPHONY an uplifting and healing movie about @JonBatiste and @suleikajaouad journey thru cancer and the healing and uniting power of his music. Thank you to Sydney Stowe for connecting.
1
4
839
Hematologists are problem-solvers. I’m proud to support the #Fight4Hematology to fund bold research and training that pushes our field forward. Donate Now [donate.hematology.org]
123
I’m riding 150 miles to support the Dartmouth Cancer Center! Day 1 tomorrow! Please support me in my emotional return to cycling! getinvolved.dartmouth-hitchc…
4
183
Handful of Monday abstracts @DartmouthCancer has worked on at #ASH24 spanning mastocytosis, CLL and hemolytic anemia. Thank you to our patients, collaborators, and pharma partners in advancing cancer care and gaining new knowledge.
6
474
Ran into the accomplished @jenamengual and her @columbiacancer team on the streets of San Diego. @MontefioreNYC connections abound with @SedaToluMD! All now tackling vexing problems in #lymphoma. Great #ASH24! Congrats Jen!
My #ASHThrowback is from 1997 in San Diego when I was a lab tech with @roberta_kato in Dr . David Rawlings lab where we were studying gene therapy for BTK in XLA. Now we are trying to inhibit and degrade BTK, and gene therapy finally made it in lymphoma CART and sickle cell.
2
285
Im looking forward to #ASH24! This year I’m interested in trying BlueSky to start a MedTwitter base there. It’s fun to try and create new things! Follow your favs like @Lymphoma_Doc @DrMiguelPerales @mtmdphd @majorajay @acweyand @TheBloodMD
#interdisciplinary paper written by our lead pharmacist, a fellow, nurse, data analyst and me!
@AmgenOncology @abbvie @genentech @Genmab @DartmouthHemOnc
Replying to @JCOOP_ASCO
This paper remains very relevant for the new BiTEs like #tarlatamab. We put @DartmouthHealth in a position to handle many admissions not just in blood cancers but in solid tumors. @DartmouthCancer innovates to serve the needs of our rural patients.
1
492
The Dartmouth Heme-Onc Fellowship Program wishes you a happy November and best of luck in the upcoming #Match! Come join us! @DartmouthHemOnc @thebloodmd @ZubairAfzalMD
@DartmouthCancer @DartmouthHealth
Dr. Anne Christine Buteau’s podium presentation of a Dartmouth Breast Cancer trial at the historic Mt. Washington Hotel. @DartmouthHemOnc @AnneChr41185205 @NNECOS_ONCOLOGY @DartmouthCancer
I’m so proud of our fellows and faculty @DartmouthHemOnc. Engaging H&N lecture by @WaspGarrett today. Then our first “Connect the Dots” Translational mixer with PhD Candidates and scientists, Drs. Prerna Malaney and Matt Hayden. Stronger together @DartmouthCancer.
I’m excited to be part of the ASH Minority Recruitment Initiative Celebration this year. The mentor-mentee relationships are so valuable and nourishing. Repping @ASH_hematology @DartmouthHemOnc @DartmouthCancer @GeiselMed @theNCI and #DEI.
Erick Lansigan retweeted
Are you an IMG or PR medical graduate?
We are still seeking participants to fill our #GoingBackHome survey.
We seek to understand the physician migration and experiences of IMG and PR graduates in the US
Please comment and we will gladly send the survey!
@SylvesterCancer
My presentation Towards Equity in Precision Medicine @NHMedSociety Annual Scientific Conference. Personalized care in pediatric oncology and Pharmacogenomics by Drs. Angela Ricci and Lionel Lewis rounded out the session. We Belong at @DartmouthCancer and we will miss Dr. Eric Loo
Erick Lansigan retweeted
ZUMA-7 is the first trial in nearly 30 years to significantly improve overall survival for patients with relapsed/refractory large B-cell in 2L therapy. Thank you to all the patients who participated in this paradigm shifting trial. #ASCO23 – at Chicago, IL
Late breaking at #ASCO23: In the phase 3 ZUMA-7 trial, patients with relapsed or refractory large B-cell lymphoma who received axi-cel (CD19-specific CAR T cells) had a 27.4% lower risk of death than patients who received standard therapy. Full trial results:
What a plenary session at #ASCO23! Annual Meeting 2023: Improving Outcomes in Glioma, Hodgkin Lymphoma, Lung Cancer, Ovarian Cancer, and Rectal Cancer. @DartmouthCancer patients contributed to #ClinicalTrials. cancer.net/blog/2023-06/asco…
Im so proud of Dr. Aditya Sharma, IM res, and our #intraprofessional education team @DartmouthCancer on our poster on Intraprofessional M&M for teaching safety and quality. Innovation is in our “blood”!
Erick Lansigan retweeted
What an amazing Dartmouth Cancer Center Reception at #ASCO23 @ASCO hosted by our chief division Dr. @LindaVahdat
Here is Dr. Konstantin Dragnev, my great mentor in thoracic malignancies, and Dr. Wong @sandralwong
I greatly admire both of them for their diligence! – at Chicago, IL




























